Supplying authorised medicines to Northern Ireland

AI Summary

Starting January 1, 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) implemented a new regulatory framework for medicinal products across the United Kingdom, in accordance with the Windsor Framework. Most medicines are now regulated through UK-wide Marketing Authorisations (MAs), utilizing the 'PL' prefix. Legacy 'PLGB' prefixes remain valid for UK-wide use, while 'PLNI' prefixes are reserved exclusively for the Northern Ireland market. A major change is that EU-issued Union authorisations are no longer valid in Northern Ireland; these products have been transitioned to UK-wide MAs and classified as Category 1 or Category 2 medicines. While this guidance does not result from specific company violations or inspections, it addresses potential compliance risks related to the post-Brexit transition. Key required actions for suppliers include ensuring that EEA-procured packs are decommissioned before being supplied to Northern Ireland and adhering to customs declaration processes for goods moving from Great Britain. Notably, the MHRA has removed the requirement for additional regulatory importation controls, such as redundant batch testing or certification, for medicines moving from Great Britain to Northern Ireland. Regulation of controlled drugs remains unchanged under existing UK legislation, such as the Misuse of Drugs Act 1971. Companies must ensure their licensing and packaging align with these updated territorial requirements to maintain lawful supply chains across the UK.